SAN DIEGO, Jan. 9, 2008 (PRIME NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (TRACON), a privately-held biopharmaceutical company focused on the development of products for oncology and ophthalmology treatment, announced today that it has dosed the initial three cancer patients in a Phase 1 clinical trial with TRC105.
